Abstract
Diabetic kidney disease (DKD) remains a major cause of chronic kidney disease, kidney failure, cardiovascular morbidity, and premature mortality despite substantial advances in renoprotective therapy. Sodium–glucose cotransporter-2 inhibitors, renin–angiotensin-system blockade, nonsteroidal mineralocorticoid-receptor antagonists, glucagon-like peptide-1 receptor agonists, and increasingly multidrug cardiorenal strategies have transformed DKD management, yet clinically meaningful residual renal risk persists. Palm-derived tocotrienol-rich vitamin E is of translational interest because it may influence oxidative, inflammatory, endothelial, metabolic, mitochondrial, and potentially fibrotic pathways that remain active during DKD progression. Direct human evidence, however, is preliminary. A Phase IIb randomized trial reported improvements in serum creatinine and estimated glomerular filtration rate, particularly in stage 3 chronic kidney disease, without corresponding improvement in albuminuria, and the apparent filtration benefit disappeared after treatment withdrawal. This qualitative review critically integrates contemporary DKD pathobiology, modern pharmacological renoprotection, tocotrienol pharmacology, randomized human evidence, and the discrepancy between filtration- and albuminuria-based endpoints. A Multi-Hit Residual Renal Risk (MHR3) model is proposed in which evidence-based pharmacotherapy constitutes the therapeutic foundation and tocotrienols are positioned only as an investigational adjunct targeting incompletely controlled biological injury. Future trials should evaluate standardized tocotrienol formulations on optimized contemporary therapy using chronic eGFR slope, repeated albuminuria, cystatin C, tubular biomarkers, mechanistic markers, pharmacokinetic exposure, safety, and adequately long follow-up.